US-Listed In Vitro & In Vivo Diagnostic Substances — Operating Income Percentiles, FY 2019

Population: 22 US-listed companies (SIC 2835), fiscal year 2019; fiscal year ends 2019-06-30 to 2020-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$-77.8M
25th percentile	$-15.9M
Median	$-2.2M
75th percentile	$26.4M
90th percentile	$83.7M
Mean	$11.1M
Minimum	$-324.8M
Maximum	$552.8M

Methodology & sources
Operating Income as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2019 = fiscal years ending 2019-06-01 to 2020-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest Operating Income percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/operating-income/2019